Dementia and Alzheimer’s Disease Treatment
TB006 Expanded Access for Dementia and Alzheimer’s Disease
TB006 is an investigational monoclonal antibody being studied for Alzheimer’s disease and related dementias. Through Expanded Access, eligible patients who cannot participate in a clinical trial and who do not have satisfactory alternative treatment options may be able to receive TB006 under physician supervision. Our role is to evaluate candidacy, review risks and benefits, coordinate required steps, and provide treatment oversight when appropriate.
Who This May Be For
This program may be appropriate for adults with symptomatic Alzheimer’s disease or related dementias who have significant unmet needs. Based on current program materials, candidates are generally 55 or older, have an estimated or actual MMSE score of 24 or less, and are unable to enroll in a clinical trial or have exhausted, not tolerated, or are not candidates for available treatment options. Final eligibility depends on physician review, current program requirements, and any required approvals.
.png)
The TB006 Expanded Access Program is designed for families seeking a more personalized, sophisticated approach to dementia care when traditional options may feel limited. While outcomes cannot be guaranteed, this investigational pathway offers access to a promising therapy within a closely supervised medical environment. Patients benefit from individualized physician oversight, attentive monitoring, and a high-touch care experience that prioritizes clarity, comfort, and thoughtful support at every step. For many, the greatest benefit is not only access to innovation, but the reassurance of navigating that process with dedicated medical guidance and exceptional continuity of care.
all inclusive direct primary care
Enjoy the benefits of Direct Primary Care with Aevita Medical through our modernized
approach to medicine made affordable, reliable and personalized for your everyday health